European UPC Ruling Refuses Block On Soliris Biosimilars
Court Values Alexion’s Disputes With Amgen And Samsung At €100m Apiece
Alexion has been refused in its bid for injunctions to block the sale of Samsung Bioepis and Amgen’s European Soliris biosimilars, following a decision by the Court of Appeal of Europe’s Unified Patent Court.
